



OPEN ACCESS

EDITED AND REVIEWED BY

Sharon R. Pine,
University of Colorado Anschutz Medical
Campus, United States

*CORRESPONDENCE

Rocío del Campo-Pedrosa
✉ rocio@encore-lab.com

RECEIVED 05 December 2024

ACCEPTED 16 December 2024

PUBLISHED 15 January 2025

CITATION

del Campo-Pedrosa R, Martín-Carnicero A,
González-Marcos A and Martínez A (2025)
Corrigendum: New model to predict
survival in advanced pancreatic ductal
adenocarcinoma patients by measuring
GGT and LDH levels and monocyte count.
Front. Oncol. 14:1540165.
doi: 10.3389/fonc.2024.1540165

COPYRIGHT

© 2025 del Campo-Pedrosa, Martín-Carnicero,
González-Marcos and Martínez. This is an
open-access article distributed under the terms
of the [Creative Commons Attribution License
\(CC BY\)](#). The use, distribution or reproduction
in other forums is permitted, provided the
original author(s) and the copyright owner(s)
are credited and that the original publication
in this journal is cited, in accordance with
accepted academic practice. No use,
distribution or reproduction is permitted
which does not comply with these terms.

Corrigendum: New model to predict survival in advanced pancreatic ductal adenocarcinoma patients by measuring GGT and LDH levels and monocyte count

Rocío del Campo-Pedrosa^{1,2*}, Alfonso Martín-Carnicero³,
Ana González-Marcos² and Alfredo Martínez⁴

¹Data Department, Encore Lab S.L., Logroño, Spain, ²Department of Mechanical Engineering, Universidad de La Rioja, Logroño, Spain, ³Medical Oncology Department, Hospital San Pedro, Logroño, Spain, ⁴Angiogenesis Group, Center for Biomedical Research of La Rioja (CIBIR), Logroño, Spain

KEYWORDS

prognosis model, prognostic biomarkers, overall survival, gamma glutamyl transferase (GGT), lactate dehydrogenase (LDH), advanced and metastatic pancreatic cancer, pancreatic ductal adenocarcinoma (PDAC)

A Corrigendum on

[New model to predict survival in advanced pancreatic ductal adenocarcinoma patients by measuring GGT and LDH levels and monocyte count](#)

By del Campo-Pedrosa R, Martín-Carnicero A, González-Marcos A and Martínez A (2024)
Front. Oncol. 14:1411096. doi: 10.3389/fonc.2024.1411096

In the published article, there was an error in **Table 4** as published. Error was in the manual transcription of the numerical data of the Kaplan-Meier result. Specifically, the transcription error has occurred for the rows of ALP, GGT and LDH. The corrected **Table 4** and its caption “Kaplan-Meier and log-rank values for statistically significant hematologic parameters grouped by the optimal cut-off” appear below.

In the published article, there was an error. The error corresponds to the paragraph in which numerical references are made to the **Table 4** with the numerical transcription error.

A correction has been made to **Results, Prognosis, Paragraph 3**. This sentence previously stated:

“Those individuals whose values on GGT and LDH were below the cut-off point (**Table 4**) presented a better prognosis than the ones who were above; specifically, they presented an OS increase by 44.8%, and 74.6%, respectively (Figures 1B, C). For their part, ALP<102.00 (Figure 1A), number of leukocytes<8,000, neutrophiles<6,000 and monocytes<800 (Figures 1D–F) were also statistically significant, resulting in patients with low levels increasing their survival by 49.7%, 44.9%, 42.5% and 44.4%, respectively (**Table 4**).”

The corrected sentence appears below:

“Those individuals whose values on GGT and LDH were below the cut-off point (**Table 4**) presented a better prognosis than the ones who were above; specifically, they presented an OS increase by 39.3%, and 49.6%, respectively (Figures 1B, C). For their part,

ALP<102.00 (Figure 1A), number of leukocytes<8,000, neutrophiles<6,000 and monocytes<800 (Figure 1D-F) were also statistically significant, resulting in patients with low levels increasing their survival by 41.8%, 44.9%, 42.4% and 44.3%, respectively (**Table 4**).”

The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

TABLE 4 Kaplan-Meier and log-rank values for statistically significant hematologic parameters grouped by the optimal cut-off.

Variable	median survival (95%CI) (months)				
	<cut-off point	≥cut-off point	N	χ^2	p-value
ALP	12.67 (10.17-17.80)	7.37 (5.77-10.10)	24/72	8.4	0.004**
GGT	12.30 (8.97-15.30)	7.47 (6.07-10.10)	31/65	4.7	0.031*
LDH	12.75 (11.40-14.57)	6.42 (4.50-8.93)	42/54	9.8	0.002**
Leukocytes	11.80 (9.50-13.40)	6.50 (4.93-9.63)	51/45	7.5	0.006**
Neutrophiles	11.15 (8.97-12.80)	6.42 (4.40-9.40)	60/36	5.1	0.024*
Monocytes	11.50 (9.50-12.90)	6.40 (5.23-8.93)	55/41	5.8	0.016*

Asterisks represent statistically significant differences. *: p<0.05; **: p<0.01.